elsilimomab
Modify Date: 2024-01-20 12:48:53
elsilimomab structure
|
Common Name | elsilimomab | ||
|---|---|---|---|---|
| CAS Number | 468715-71-1 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of elsilimomabElsilimomab (B-E8) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA)[1][2][3]. |
| Name | elsilimomab |
|---|
| Description | Elsilimomab (B-E8) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA)[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
IL-6:1.4 nM (IC50) |
| In Vitro | Elsilimomab 特异性抑制 IL-6，但不抑制 LIF (白血病抑制因子)诱导的细胞生长[2]。 Elsilimomab (20 μg/mL) 可中和人 IL-6[2]。 Cell Viability Assay[2] Cell Line: Murine B9 cells Concentration: 20 μg/mL Incubation Time: 3 days Result: B9 cells were stimulated with human IL-6, which was effectively neutralized by antibody Elsilimomab. |
| References |
| No Any Chemical & Physical Properties |